MINocyclinE to Reduce inflammation and blood-brain barrier leakage in small Vessel diseAse (MINERVA): A phase II, randomized, double-blind, placebo-controlled experimental medicine trial

DISCUSSION: 11C-PK11195 binding and increased BBB permeability are present in SVD; minocycline did not reduce either process. Whether these pathophysiological mechanisms are disease-causing remains unclear.INTERNATIONAL CLINICAL TRIALS REGISTRY PORTAL IDENTIFIER: ISRCTN15483452 HIGHLIGHTS: We found focal areas of increased microglial signal and increased blood-brain barrier permeability in patients with small vessel disease. Minocycline treatment was not associated with a change in these processes measured using advanced neuroimaging. Blood-brain barrier permeability was dynamic but MRI-derived measurements correlated well with CSF/serum albumin ratio. Advanced neuroimaging is a feasible outcome measure for mechanistic clinical trials.PMID:38629936 | DOI:10.1002/alz.13830

Source: The Journal of Alzheimers Association - April 17, 2024 Category: Psychiatry Authors: Robin B Brown Daniel J Tozer Laurence Loubi ère Eric L Harshfield Young T Hong Tim D Fryer Guy B Williams Martin J Graves Franklin I Aigbirhio John T O'Brien Hugh S Markus Source Type: research